0RV2.LSE BioArctic AB Series B

Healthcare Commercial Services & Supplies London Exchange
- SEK
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
0.59%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0RV2.LSE undervalued?

Graham number

The Graham number of BioArctic AB Series B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioArctic AB Series B fundamental analysis

No fundamental analysis for BioArctic AB Series B yet.

BioArctic AB Series B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioArctic AB Series B

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatm…

Full company profile